Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

GastroEsophageal Cancer × bemarituzumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 6 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Adenocarcinoma 2 Triple Negative Breast Neoplasms 1 Squamous-Cell Non-Small-Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 Gastrointestinal Neoplasms 1 GastroEsophageal Cancer 1 Gastric or Gastroesophageal Cancer 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Adenocarcinoma of Lung 1

Interventions

Surveys and Questionnaires 2 bemarituzumab 1 Radiotherapy 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Lapatinib 1 Irinotecan 1 Immune Checkpoint Inhibitors 1 Fluorouracil 1 Exercise 1 Diet Therapy 1 Carboplatin 1 Capecitabine 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06978062 2025-06-05

NeoBEMA

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Not yet recruiting

Gastrointestinal

GastroEsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡